Novo Nordisk México Appoints New General Director to Drive Innovation

Novo Nordisk México, a subsidiary of one of the world's most influential healthcare companies, formalized the appointment of Patricia Field de León as its new General Director. This is a strategic move aimed at accelerating scientific innovation, expanding access to cutting-edge therapies, and consolidating Mexico's role as a key hub in Latin America. With over 24 years of international experience in the pharmaceutical and consumer goods industries, Field de León took the helm of the Mexican operation at a time of high relevance for public health, marked by the growing burden of serious chronic diseases such as diabetes, obesity, and rare ailments, as well as the need for more equitable and sustainable care models. An economist with an MBA, Patricia Field de León built an executive career in highly complex markets such as Ecuador, Brazil, the United States, and Colombia. Under her leadership, Novo Nordisk México will reinforce one of its central strategic axes: recognizing obesity as a multifactorial chronic disease, and not merely an aesthetic problem. The company will also strengthen its investment in clinical research, digital transformation, and the development of specialized talent, as part of its commitment to a more robust, inclusive, and sustainable healthcare system. With 20 years of operation in the country, Novo Nordisk has been recognized as a Great Place to Work and as an ethical company with an inclusive culture. It leads the comprehensive approach to chronic diseases, develops community programs like 'Cities Changing Diabetes,' and maintains alliances with UNICEF to combat childhood obesity, consolidating a strategy that integrates science, community, and social responsibility. Before taking the helm in Mexico, she headed Novo Nordisk Colombia for over three years, driving organizational transformation, sustainability, and cultural strengthening processes, even in challenging regulatory contexts. Her career also includes her role as General Manager of Biogen in Colombia and a decade as Commercial Director for Latin America at AbbVie, in addition to strategic positions at Mars Inc., which gave her a comprehensive vision of innovation, operations, and corporate leadership. In addition to her corporate profile, Field has had a prominent role in the institutional sphere as President of the Board of Directors of AFIDRO, the main association of the innovative pharmaceutical industry in Colombia. From this position, she promoted public policies aimed at expanding access to treatments and improving the quality of life for millions of people. In parallel, she has driven gender equity and female leadership initiatives, leading projects such as MpoderayfloreSER, focused on stimulating the participation of girls and young women in STEM areas (Science, Technology, Engineering, and Mathematics). In 2025, Forbes included Patricia Field de León on its list of 'The 100 Most Powerful Women in Colombia,' highlighting her influence as an executive leader in contemporary debates on health, equity, and authentic leadership, understood as a form of close, inclusive, and people-centered management. The appointment marks a new era of innovation, equity, and healthcare leadership in the country.